Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
American Heart Journal|July 10, 2003
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineVojtech Melenovsky, Tomas Stulc, Viktor Kozich, et al.The New England Journal of Medicine|September 15, 2006
Oral fingolimod (FTY720) for relapsing multiple sclerosisLudwig Kappos, Jack Antel, Giancarlo Comi, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|December 22, 2006
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipientsHelio Tedesco-Silva, Stefan Vitko, Julio Pascual, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studiesStefan Vitko, Helio Tedesco, Josette Eris, et al.The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJames C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.The Lancet. Oncology|February 17, 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.Pageof 2